Antimicrobial Stewardship in Canine Otitis: Culture, Susceptibility, and Topical Therapy

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Cytology of otic exudate is the critical first-line diagnostic step to differentiate bacterial cocci, bacterial rods, or yeast, guiding initial therapeutic decisions.
• Culture and susceptibility testing are indicated for rod-shaped bacteria on cytology, chronic or recurrent otitis, prior treatment failure, or suspected multidrug-resistant infections to ensure targeted antimicrobial selection.
• Topical therapy is the preferred antimicrobial route for otitis externa without systemic signs, delivering high local drug concentrations and minimizing systemic antibiotic selection pressure.
• Systemic antibiotic administration is reserved for deep infections, systemic illness, severe ulceration, or immunocompromised patients, and should be guided by culture and susceptibility data when feasible.
• Fluoroquinolone resistance in Pseudomonas aeruginosa is a significant concern, necessitating culture and susceptibility testing before empirical fluoroquinolone use in rod-dominated otitis.
• Emerging antimicrobial options like ionophores (narasin, monensin) demonstrate in vitro activity against Gram-positive otic pathogens and may offer alternatives that avoid classes critical to human medicine.

Canine otitis externa is one of the most frequent reasons for antimicrobial prescribing in small animal practice, yet much of that prescribing is unnecessary. The external ear canal is accessible to topical therapy, which can deliver drug concentrations far above systemic levels while avoiding the selection pressure that accompanies whole-body antibiotic exposure. This article provides a procedural framework for managing canine otitis with a stewardship-first approach: cytology to classify the infection, culture and susceptibility testing to guide drug selection when bacteria are present, and topical formulations as the primary therapeutic route. It is written for practicing veterinarians who want a defensible, repeatable decision pathway that reduces systemic antibiotic use without compromising clinical outcomes.

The clinical question this article answers is direct: when a dog presents with otitis, which cases require systemic antibiotics, which require only topical therapy, and how should the clinician choose the drug? The answer depends on distinguishing infection from inflammation, identifying the organizm class, and recognizing that the ear canal's anatomy and physiology make it uniquely suited to local treatment. The article also addresses the emerging resistance patterns in common otic pathogens and the evidence for alternative antimicrobial agents that are not used in human medicine.

At a Glance

Pathophysiology of the Otic Environment

The external ear canal is a blind-ended tube lined by stratified squamous epithelium with a thin stratum corneum. Its vertical and horizontal components create a warm, moist, dark environment that supports microbial proliferation when normal defenses fail. Cerumen provides a physical barrier and contains antimicrobial lipids, but excessive moisture, maceration, or foreign material disrupts this protection. The canal's epithelium has a limited capacity for repair, and chronic inflammation leads to hyperplasia, glandular hypertrophy, and stenosis that further impairs drainage and ventilation.

The microbiology of canine otitis reflects this environment. Staphylococcus pseudintermedius and Malassezia pachydermatis are the most common isolates, followed by Pseudomonas aeruginosa and Proteus mirabilis in chronic or previously treated cases. The distinction matters clinically because Gram-positive cocci and yeast respond to a different topical drug selection than Gram-negative rods. Cytology provides this distinction within minutes and should precede any antimicrobial decision. A study of staphylococcal isolates from canine otitis cases in Western Romania found that species identification and susceptibility profiling were essential for guiding therapy, given the variability in resistance phenotypes among clinical isolates.

Antimicrobial Resistance in Otic Pathogens

Resistance patterns in canine otic isolates have shifted in ways that directly affect empirical drug choices. A Romanian study of 435 dogs with otitis externa isolated P. aeruginosa in 14.0% of cases. All isolates were susceptible to amikacin and gentamicin, but resistance to enrofloxacin and marbofloxacin reached 27.9%, and pradofloxacin resistance was 63.9%. Only 24.6% of isolates were susceptible to all tested antibiotics. These figures illustrate a central stewardship problem: fluoroquinolones, a critically important class for human medicine, are losing efficacy against a common canine otic pathogen, and empirical use of this class is increasingly difficult to justify.

The same study noted that multidrug-resistant phenotypes were frequent, reinforcing the need for culture and susceptibility testing before selecting a fluoroquinolone for any rod-dominated otitis. The AVMA antimicrobial use and stewardship resources emphasize that resistance emerges through selective pressure, and each unnecessary systemic fluoroquinolone course contributes to that pressure in both the individual patient and the broader bacterial population.

Topical Therapy as the Default Route

The ear canal's accessibility makes topical therapy the logical first choice for otitis externa. Topical formulations deliver drug concentrations that exceed the minimum inhibitory concentration (MIC) of most pathogens by orders of magnitude, and they do so without measurable systemic absorption in most cases. This pharmacokinetic advantage means that an antibiotic that appears resistant by systemic breakpoints may still be effective topically, because the local concentration overwhelms the resistance mechanism. The MSD Veterinary Manual notes that topical otic preparations are the mainstay of treatment for otitis externa, with systemic therapy reserved for cases involving the middle ear or systemic illness.

Topical therapy also reduces the risk of adverse systemic effects and avoids disruption of the gastrointestinal and cutaneous microbiota. For stewardship purposes, the key principle is that topical antibiotics should be selected based on cytology and, when bacteria are present, culture results. Empirical topical therapy with a broad-spectrum preparation is acceptable for a first episode of uncomplicated otitis, but chronic or recurrent cases warrant a more deliberate approach.

Culture and Susceptibility Testing

Culture is indicated when cytology reveals rods, when the infection is chronic or recurrent, when previous therapy has failed, or when the clinician suspects a multidrug-resistant organizm. The WOAH terrestrial animal health code identifies antimicrobial susceptibility testing as a core component of responsible antimicrobial use in animals. Sampling technique matters: a sterile swab should be inserted into the horizontal canal after cleaning debris from the vertical canal, and the sample should be submitted with a request for both aerobic culture and susceptibility testing.

Interpretation of susceptibility results requires attention to the testing method and breakpoints. The Clinical Laboratory Standards Institute (CLSI) VET01 document provides veterinary-specific breakpoints, and laboratories should be asked to report results using these standards. A systemic susceptibility result does not directly predict topical efficacy, but it provides a starting point for drug selection. When a pathogen is resistant to all tested systemic antibiotics, topical therapy may still succeed, and the ionophore data discussed below offer additional options.

Emerging Antimicrobial Options

The search for antimicrobials that are not used in human medicine has identified ionophores as candidate agents for otic formulations. Narasin and monensin are polyether ionophores conventionally used in production animals as anticoccidial agents and rumen modifiers. In vitro testing of narasin against 110 clinical isolates from canine otitis found MICs of 0.06 to 0.25 μg/mL for staphylococci and streptococci, including multidrug-resistant S. pseudintermedius strains. Monensin showed similar activity against Gram-positive isolates, with MICs of 1 to 4 μg/mL, but lacked activity against Gram-negative bacteria and yeast.

Combination studies have explored ionophores with adjuvants. Narasin combined with Tris-EDTA or disodium EDTA produced additive effects against P. aeruginosa strains, and monensin combined with N-acetylcysteine reduced the monensin MIC by up to 32-fold against S. aureus. These findings suggest that ionophore-based topical formulations could provide an antimicrobial option that avoids classes critical to human medicine, though clinical trials are needed before routine use. The FDA Center for Veterinary Medicine regulates approved animal drugs and compounding, and any novel otic formulation must comply with applicable regulatory requirements.

Clinical Assessment Sequence and Decision Points

The diagnostic pathway for canine otitis follows a predictable sequence, but the depth of each step varies with case chronicity, prior treatment, and clinical presentation. For a first presentation of acute otitis externa without systemic signs, the minimum database consists of otoscopic examination of both ear canals and tympanic membranes, cytology from the affected ear, and assessment of the external ear canal lumen for stenosis or proliferative change. This initial evaluation determines whether the case can proceed directly to topical therapy or requires culture, imaging, or systemic antimicrobials.

Cytology is the single most informative rapid test available. A swab from the horizontal canal, rolled onto a glass slide and stained with Diff-Quik or equivalent, provides immediate information about the presence of cocci, rods, yeast, and inflammatory cells. The distinction between cocci and rods is clinically critical because it changes the initial topical drug selection. Cocci suggest staphylococcal infection, while rods raise suspicion for Pseudomonas aeruginosa or Proteus mirabilis, organizms with substantially different susceptibility profiles and treatment implications. The density of organizms per high-power field, combined with the ratio of degenerate to non-degenerate neutrophils, helps stage severity and monitor response to therapy.

The decision to culture should follow explicit criteria instead of habit. Culture and susceptibility testing is indicated when cytology reveals rods, when the patient has received more than two weeks of topical or systemic antimicrobial therapy without resolution, when there is recurrent otitis within a short interval, when the tympanic membrane is ruptured or cannot be visualized, or when systemic signs such as fever, pain on opening the mouth, or vestibular signs are present. Culture is also appropriate before any systemic antimicrobial use, because systemic therapy for otitis is reserved for specific indications and should be guided by susceptibility data whenever possible.

Topical Versus Systemic Antibiotic Selection

The default route for antimicrobial delivery in otitis externa is topical. The otic environment is accessible, drug concentrations achieved by topical application far exceed those possible with systemic administration, and systemic side effects are avoided. Systemic antimicrobials are indicated only when the infection extends beyond the external canal, when the tympanic membrane is ruptured and the middle ear is involved, when there is severe soft tissue swelling that prevents topical drug penetration, or when the patient cannot tolerate ear cleaning or topical application. Systemic therapy is also appropriate for immunocompromised patients and for cases where the owner cannot reliably administer topical medication.

When systemic therapy is required, the choice of agent should be informed by culture results. The resistance patterns reported in regional studies illustrate why empirical systemic selection is unreliable. In one Romanian study of Pseudomonas aeruginosa isolates from canine otitis, all isolates were susceptible to amikacin and gentamicin, but resistance to enrofloxacin and marbofloxacin reached 27.9% and pradofloxacin resistance reached 63.9%. A separate study of Staphylococcus species from the same region documented variable susceptibility profiles that would make empirical fluoroquinolone use a poor first choice. These findings support the position that systemic antimicrobials for otitis should be culture-driven, not empirical, except in the most acute and uncomplicated presentations.

Topical Agent Selection and Formulary Considerations

Topical therapy offers the advantage of delivering drug concentrations that exceed the minimum inhibitory concentration by orders of magnitude, which can overcome resistance that would be clinically significant with systemic administration. The selection of a topical agent should be guided by cytology, the integrity of the tympanic membrane, and the known spectrum of the formulation.

The choice between commercially available combination products and compounded formulations depends on the clinical situation. Commercial products offer convenience, stability, and approved labeling. Compounded products allow customisation of drug concentration and vehicle, which may be necessary for resistant organizms or for patients with contact sensitivity to commercial vehicles. When compounding is considered, the veterinarian must verify the stability and compatibility of the components and document the rationale in the medical record. Regulatory requirements for compounding vary by jurisdiction, and practitioners should consult their local regulatory authority for current policy.

Monitoring Parameters and Recheck Intervals

Treatment monitoring follows a structured schedule that balances the need for confirmation of resolution against the cost and stress of repeated visits. The first recheck should occur at 7 to 10 days after initiation of topical therapy. At this visit, otoscopy and cytology are repeated. Improvement is defined by a reduction in organizm numbers, a shift from degenerate to non-degenerate neutrophils, and reduced erythema and exudate. If cytology shows persistent rods or cocci at the same density as the initial visit, the treatment plan requires revision. This may mean changing the antimicrobial, adding a Tris-EDTA flush, or reconsidering the diagnosis.

A second recheck at 21 to 28 days is appropriate for chronic cases or those that required culture. The goal is cytologic resolution, also clinical improvement. Clinical signs may resolve while low-grade infection persists, and stopping treatment on the basis of clinical appearance alone invites early recurrence. Cytology at this visit should show no organizms or only rare extracellular bacteria with no degenerate neutrophils. If the ear is cytologically clear but clinically abnormal, the differential diagnosis shifts to non-infectious causes such as allergic disease, foreign body, or neoplasia.

For cases that required systemic antimicrobials, the same recheck schedule applies, but the duration of systemic therapy should be defined at the outset. Systemic therapy for otitis is typically short, and the response to treatment should be assessed at the first recheck to determine whether continuation is necessary. Prolonged systemic therapy without cytologic or culture-based justification is a common stewardship failure.

Documentation and Stewardship Integration

The medical record should document the cytology findings at each visit, the topical and systemic drugs used with their routes and durations, the results of culture and susceptibility testing when performed, and the rationale for any systemic antimicrobial use. This documentation serves multiple purposes. It provides a baseline for comparison at recheck visits, supports the clinical reasoning if the case is reviewed, and creates a practice-level dataset that can be audited for antimicrobial use patterns.

Practices that track their own antimicrobial prescribing can identify trends such as excessive fluoroquinolone use or systemic therapy for uncomplicated otitis. Professional guidance on judicious antimicrobial use emphasizes the importance of such internal review as part of a broader stewardship program. International standards for antimicrobial resistance surveillance and responsible use also support the collection of practice-level data as a component of veterinary antimicrobial stewardship. The individual clinician contributes to this effort by treating each case of otitis as an opportunity to apply the principles of targeted, topical-first, culture-guided therapy.

Recognized Complications and Early Detection

The most consequential failure in otitis management is progression from external to middle ear disease. A dog that fails to improve after seven to ten days of appropriate topical therapy, or that deteriorates after initial improvement, warrants otoscopic re-examination under sedation or anesthesia to assess tympanic membrane integrity. Rupture of the tympanum changes both drug selection and contraindications: ototoxic agents such as aminoglycosides and chlorhexidine must be avoided when the membrane is compromised. Serial video-otoscopic examination provides the most reliable monitoring for membrane integrity, but pneumatic otoscopy and diagnostic imaging serve as alternatives when video equipment is unavailable.

Treatment failure with Pseudomonas aeruginosa demands particular scrutiny. The Romanian surveillance study of 435 dogs with otitis externa isolated P. aeruginosa in 14.0% of cases, with fluoroquinolone resistance present in 27.9% of isolates for enrofloxacin and marbofloxacin and 63.9% for pradofloxacin, while all isolates remained susceptible to amikacin and gentamicin. These figures illustrate why empirical fluoroquinolone therapy for a suspected pseudomonal infection carries a substantial risk of failure. Early detection of this scenario requires cytology at every recheck: persistence of rod-shaped bacteria with intracellular uptake on stained smears, despite an appropriate topical fluoroquinolone, should trigger culture and susceptibility testing instead of a simple switch to another drug in the same class.

Biofilm formation represents a second, frequently missed complication. Pseudomonas and Staphylococcus species adherent to the epithelial surface or embedded within ceruminous debris are poorly eradicated by antimicrobials alone. Mechanical cleansing, performed under general anesthesia when the ear is painful, disrupts biofilm architecture and is a prerequisite for topical drug penetration. The in vitro work on ionophores combined with adjuvants demonstrated additive effects against P. aeruginosa when narasin was paired with Tris-EDTA or disodium EDTA, and against Staphylococcus aureus when narasin or monensin was combined with N-acetylcysteine, with dose reduction indices up to 32-fold for the monensin and N-acetylcysteine combination. These findings support the clinical practice of incorporating ceruminolytic and biofilm-disrupting agents into the treatment plan, although the studies used reference strains and a single clinical Proteus isolate, so extrapolation to field conditions requires caution.

Common Errors and Corrective Actions

Less experienced clinicians frequently mistake the absence of visible discharge for resolution of infection. Cytology, not visual inspection, defines cure. A dog with a dry, mildly erythematous canal can still harbour abundant cocci or yeast in the deeper horizontal canal. The corrective habit is to perform cytology at every recheck and to continue treatment until the smear shows no organizms, also until the ear looks clean.

A second recurring error is the reflexive prescription of systemic antibiotics for a condition that is anatomically accessible to topical therapy. The Australian prescribing survey found that empirical antimicrobial therapy was used in 76% of acute conditions and 24% of chronic conditions, with potentiated aminopenicillins the most common class overall. Systemic antibiotics add cost, risk of adverse effects, and selection pressure for resistance without improving penetration into the otic canal. The corrective action is to ask, before writing a systemic prescription, whether the tympanic membrane is intact and whether a topical formulation can reach the affected tissue. If both answers are favourable, topical therapy is the default.

A third error involves the indiscriminate use of fluoroquinolone-containing topical products without cytological confirmation of bacterial infection. Malassezia overgrowth, which is common in allergic otitis, does not respond to antibacterial agents. The corrective action is to stain and examine every ear smear, classify the organizm population, and select the topical product accordingly.

Limitations of the Evidence and Divergent Expert Opinion

The evidence base for otic antimicrobial therapy carries notable constraints. Susceptibility data from Romanian surveillance studies reflect regional resistance ecology and may not transfer to other geographic areas. The ionophore studies examined in vitro activity only, no clinical efficacy trials have established that narasin or monensin in otic formulations outperforms conventional agents in dogs. Expert opinion diverges on the role of systemic antibiotics in chronic otitis with an intact tympanic membrane. Some clinicians advocate systemic therapy for deep-seated infection of the horizontal canal, arguing that topical penetration is unreliable in a stenotic, hyperplastic canal. Others maintain that aggressive ear flushing under anesthesia, followed by topical therapy, achieves equivalent results without systemic exposure. The evidence does not yet resolve this disagreement, and the clinician must weigh the severity of canal pathology, the presence of systemic signs, and the owner's capacity for home treatment.

Escalation, Referral, and Reporting

Referral to a veterinary dermatologist or a surgeon with advanced otoscopy capability is warranted when any of the following circumstances arise: suspected or confirmed middle ear disease, recurrent otitis exceeding three episodes in twelve months, suspected neoplastic or polypoid masses within the canal, or failure to improve after two courses of appropriately selected topical therapy. Laboratory involvement is indicated earlier instead of later when cytology shows rods, when multidrug resistance is suspected, or when the dog has received multiple antibiotic courses in the preceding year.

Regulatory reporting obligations vary by jurisdiction. Suspected adverse drug reactions, including ototoxicity attributed to a licensed topical product, should be reported to the relevant national pharmacovigilance system. The FDA Center for Veterinary Medicine maintains adverse event reporting pathways for products used in the United States, and the AVMA provides guidance on judicious antimicrobial use that incorporates resistance monitoring. International movement of dogs with resistant infections may implicate the World Organization for Animal Health terrestrial animal health standards, particularly where trade or travel documentation requires declaration of antimicrobial treatment.

Frequently Asked Questions

How Should I Proceed When Cytology Shows Bacteria but Culture Is Not Feasible?

When culture is unavailable or cost-prohibited, cytology-guided topical therapy remains the first-line approach. Select a topical product with activity against the morphotype identified. Cocci suggest staphylococci, and rods suggest Pseudomonas or Proteus. For rods, choose a product containing an aminoglycoside or a fluoroquinolone, recognizing that resistance is possible. Recheck cytology at 7 to 14 days. If rods persist despite appropriate topical therapy, culture becomes necessary even if it requires referral or a delayed sampling visit. Document the limitation in the medical record and revisit systemic therapy only if clinical deterioration or extension beyond the ear canal develops. Regional susceptibility data can guide empirical topical selection when individual culture is not possible, as resistance patterns vary geographically.

What Are the Practical Barriers to Routine Culture in General Practice?

Cost to the owner is the most common barrier, followed by laboratory turnaround time and the perceived need to start treatment immediately. A practical compromise is to initiate topical therapy for 5 to 7 days, then collect culture samples at the recheck visit if cytology shows persistent infection. This approach allows initial relief while still obtaining culture before additional antibiotic pressure. Some practices reduce cost by submitting swabs only for chronic, recurrent, or rod-dominated infections. Discuss the cost of culture against the cumulative cost of repeated failed topical treatments. A single culture that identifies a resistant Pseudomonas and directs effective therapy often costs less than multiple empirical treatment courses.

How Do I Explain the Need for Culture to a Client Who Wants a Quick Fix?

Frame culture as the tool that prevents wasted treatments and repeated visits. Explain that ear infections in dogs are often caused by bacteria that do not respond to the first antibiotic chosen, and that the culture test identifies which drug will work. Use the analogy of a key fitting a lock. Emphasize that topical ear medication is the primary treatment and that oral antibiotics are reserved for specific situations such as severe swelling, perforated tympanic membranes, or systemic illness. Reassure the owner that culture does not delay treatment because topical therapy starts immediately. Most owners accept culture when it is presented as a way to avoid prolonged or repeated treatment.

When Is Systemic Antibiotic Therapy Justified Despite a Topical-First Approach?

Systemic therapy is indicated when the tympanic membrane is ruptured and a potentially ototoxic topical agent would be used, when otitis media is confirmed or strongly suspected, when there is severe pinnal or periauricular cellulitis, or when the patient is systemically unwell. Systemic antibiotics are also appropriate when the ear canal is so stenotic or painful that topical delivery cannot reach the affected tissue. In these cases, obtain culture samples before starting systemic therapy whenever possible. Choose a systemic agent based on culture and susceptibility results instead of empirical selection. Re-evaluate the need for continued systemic therapy at each recheck, and discontinue it once the infection is controlled and topical therapy can be delivered effectively.

How Should I Document Stewardship Decisions in the Medical Record?

Record the cytology findings with the specific morphotype and quantity, the product selected and the rationale, and whether culture was performed or declined. If culture was declined, note the owner's decision and the discussion that occurred. Document the recheck interval and the criteria that would trigger culture or escalation. For systemic antibiotic use, record the indication, the drug selected, the expected duration, and the plan for reassessment. This documentation supports defensible prescribing and allows audit of your own prescribing patterns over time. Professional guidance on judicious antimicrobial use supports this level of record keeping as part of stewardship integration in practice.

Does This Approach Apply to Cats or Other Species?

The principles of topical-first therapy and culture-guided selection apply broadly, but the product options and common pathogens differ. Cats develop otitis externa less frequently than dogs, and the underlying causes, such as polyps or nasopharyngeal disease, require different diagnostic attention. Some topical products approved for dogs are not labelled for cats, and the risk of adverse reactions differs. Check the label for species approval before use. In production animals, otitis is managed differently and may involve herd-level considerations and withdrawal periods that do not apply in companion animal practice. International standards for antimicrobial use vary by region and species, so consult local guidance and approved product labeling.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Antimicrobial Susceptibility and Fluoroquinolone Resistance Patterns of &lt,i&gt,Pseudomonas aeruginosa&lt,/i&gt, Isolated from Canine Otitis Externa in Romania.. 2026.
• In vitro antimicrobial activity of narasin against common clinical isolates associated with canine otitis externa.. 2018.
• In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa.. 2020.
• Future Challenge: Assessing the Antibiotic Susceptibility Patterns of <i>Staphylococcus</i> Species Isolated from Canine Otitis Externa Cases in Western Romania.. 2024.
• In vitro antimicrobial activity of monensin against common clinical isolates associated with canine otitis externa.. 2018.
• Antimicrobial Prescribing in Dogs and Cats in Australia: Results of the Australasian Infectious Disease Advisory Panel Survey.. 2017.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Antimicrobial Stewardship in Canine Bite Wounds: Culture and Susceptibility-Driven Therapy
• Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer
• Antimicrobial Stewardship in Canine Periodontal Disease: Antibiotic Use in Dentistry
• Antimicrobial Stewardship in Canine Postoperative Infections: Prevention and Treatment
• Antimicrobial Stewardship in Food Animals: Principles and Practical Application

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.